Scientific Temper

Biotechnology

Medicines from biotechnology: proteins, antibodies, vaccines and cancer

Builds on: From rDNA to gene editing (recombinant DNA) and Gene therapy (gene therapy, CAR-T).

In a nutshell

Most of biotechnology's effect on health is not gene therapy at all. It is the manufacture of proteins that the body needs or that fight disease: insulin, clotting factors, antibodies and vaccines. All of these work on the immune system or on the body's own chemistry, and they are made by engineered cells rather than by chemical synthesis.

  1. Proteins as medicines: made by engineered microbes or cells (recombinant DNA).
  2. Vaccines: show the immune system a pathogen's marker before the real infection.
  3. Hard problems: cancer, which is our own cells, and microbes that outrun our drugs.

Known protein or antigenEngineered cells make itMedicine or vaccine

Until the early 1980s, a person with type 1 diabetes injected insulin extracted from the pancreases of slaughtered pigs and cattle; about two tonnes of pig pancreas gave eight ounces of insulin. Today the same hormone is made by bacteria in a fermenter, and it is human insulin, not pig insulin. The same shift, from extracting a substance to instructing cells to make it, lies behind most new medicines.

Therapeutic proteins

Many diseases come from a protein the body cannot make. The recombinant DNA route (see From rDNA to gene editing) is to put the human gene into a microbe or cultured cell, grow it in large vessels, and purify the protein. Because the protein is the human version, it works better and provokes fewer reactions than one taken from an animal.

  • Insulin. In the pancreas, clusters of cells called the islets of Langerhans contain beta cells that release insulin; insulin is the signal that lets cells take glucose from the blood. In type 1 diabetes the beta cells are destroyed, so insulin must be supplied. In type 2 diabetes insulin is made but the cells respond to it poorly (insulin resistance). Human insulin made in E. coli was the first recombinant medicine (approved 1982); in India, Biocon and others make recombinant insulin.
  • Clotting factors for haemophilia: factor VIII or IX, which stop bleeding from continuing (see Gene therapy). Recombinant factors avoid the risk of infection that came with factors purified from donated blood.
  • Human growth hormone, erythropoietin (which stimulates red cell production, used in kidney failure), interferons and enzymes for rare metabolic diseases.

These are biologics (see Reading the genome): large molecules made by living cells, unlike the small chemical molecules of most tablets, and copied after patent expiry as biosimilars rather than exact generics.

The immune system in brief

Everything that follows needs a few terms. The immune system has two layers:

  • Innate immunity: the barriers and general defences you are born with: skin, stomach acid, inflammation, and cells that swallow anything foreign. Fast, but not specific.
  • Adaptive (acquired) immunity: defences built against a particular invader, and remembered. It is carried by two kinds of white blood cell: B cells, which make antibodies, and T cells, which kill infected or abnormal cells and help organise the response.

An antigen is any molecule on a pathogen that the immune system can recognise: in the lock-and-key picture of a cell's surface (see The cell), it is a label the body learns to read. An antibody is a protein made by B cells that binds one particular antigen, marking the invader for destruction. A pathogen carries many antigens, so the body makes many different antibodies against it: a polyclonal response. The first time, this takes days or weeks; afterwards, memory cells make the response fast enough to prevent illness. That is the immunity a vaccine creates in advance.

Monoclonal antibodies

For treatment, one well-chosen antibody is often better than the body's mixture, because it can be selected to block the exact target that matters, made in quantity and given at once. Monoclonal antibodies are identical copies of a single antibody, grown from one clone of cells. The original method (Köhler and Milstein, Nobel Prize 1984) fused an antibody-making cell with a cancer cell so that it would divide indefinitely; today they are produced by recombinant DNA technology in cultured cells. Uses:

  • Cancer: antibodies that bind a protein on tumour cells, such as trastuzumab in some breast cancers; or checkpoint inhibitors, which block the molecular brakes that tumours use to switch off T cells, so the immune system attacks the tumour (Nobel Prize 2018).
  • Autoimmune and inflammatory disease: antibodies that neutralise inflammatory signals, used in rheumatoid arthritis and psoriasis.
  • Infection: antibodies given as treatment, used against COVID-19 and rabies; a monoclonal antibody for RSV protects infants.
  • Diagnosis: the lines on a pregnancy test or a rapid antigen test are antibodies binding their target.

Names are a clue: monoclonal antibodies end in -mab.

Vaccines: showing the label in advance

A vaccine presents the immune system with a pathogen's antigen so that memory is in place before the real infection. The types differ in how the antigen is presented.

TypeWhat is givenNotesExample
Live attenuatedThe whole pathogen, weakened so that it cannot cause diseaseStrong, lasting immunity; usually not given to people with weak immunity; needs a cold chainBCG, measles, oral polio, chickenpox
Inactivated (killed)The whole pathogen, killedSafer but weaker; boosters neededInjectable polio; Covaxin (India, Bharat Biotech and ICMR)
Subunit, recombinant or conjugateOnly a piece of the pathogen, usually one protein, often made by engineered cellsVery safe; needs an adjuvant, a substance that strengthens the responseHepatitis B; HPV vaccine; Cervavac (India's quadrivalent HPV vaccine, launched 2022)
Viral vectorA harmless virus carrying the gene for one antigen, which the body's cells then makeStrong cellular response; immunity to the vector can limit repeat dosesCovishield (the Oxford-AstraZeneca vaccine made by Serum Institute of India)
mRNAThe messenger RNA for one antigen, wrapped in lipid nanoparticles; the body's own ribosomes make the proteinFast to design and to redesign for a new variant; no live pathogen; most need deep cold storagePfizer and Moderna COVID-19 vaccines; GEMCOVAC-OM (India's first mRNA vaccine, Gennova, 2023, which is stable at ordinary refrigerator temperature and needle-free)
DNADNA for the antigen, transcribed and then translated in the bodyStable, cheap; immune response generally weaker than mRNAZyCoV-D (Zydus, 2021), the world's first approved DNA vaccine for humans

Note what an mRNA vaccine does not do: it does not enter the nucleus or change your DNA, and the RNA is broken down within days (see DNA as the code of life). Its value is speed, which is why mRNA platforms are being developed for tuberculosis, Nipah and cancer.

Why malaria resisted vaccination for a century

Malaria is caused not by a virus or a bacterium but by Plasmodium, a single-celled eukaryote with a complicated life cycle: it passes from a mosquito into the bloodstream, multiplies in the liver, emerges to infect red blood cells, and later forms sexual stages taken up by another mosquito. At each stage it displays different surface proteins, so antibodies raised against one stage do not recognise the next. That is also why people in malarial regions suffer repeated attacks without becoming immune: natural infection does not produce lasting protection against a target that keeps changing its label. (The same difficulty, in a different form, affects HIV, which mutates very rapidly, and influenza, whose surface proteins change every year, which is why flu vaccines are reformulated annually.)

Both approved malaria vaccines target the parasite's earliest stage, before it reaches the liver. RTS,S (Mosquirix, GSK) was recommended by the WHO in 2021, the first malaria vaccine and the first for any human parasitic disease. R21/Matrix-M, developed by Oxford's Jenner Institute and the Serum Institute of India, was recommended in October 2023; it is cheaper and can be made in very large volumes. Both are for children in malaria-endemic areas, mainly in Africa; they reduce cases substantially but are not a complete shield, so bed nets and treatment remain necessary.

Cancer

A cell that should stop dividing, or die by apoptosis (see The cell), keeps dividing instead. The faults are in the genes that control division: oncogenes drive division when they are overactive, and tumour suppressor genes normally apply the brakes, so losing them removes the brake. Because the controls are layered, cancer usually needs several such changes, which is why it is largely a disease of later life and why mutation-causing agents (tobacco smoke, radiation, some chemicals and some infections) raise the risk.

The growing mass takes nutrients and space from healthy tissue. While it stays within its boundary it is benign; once cells break through into blood or lymph and settle elsewhere, the cancer is malignant, and that spread, metastasis, is what makes it hard to treat. The hardest problem is that cancer cells are the patient's own: there is little that is foreign for a drug or the immune system to recognise.

Hence the direction of treatment, from general to targeted:

  • Surgery, where the tumour can be removed.
  • Chemotherapy: drugs that kill rapidly dividing cells. They also hit healthy dividing cells, in hair follicles, the gut lining and bone marrow, which is where the side effects come from.
  • Radiotherapy: high-energy radiation, usually gamma rays or X-rays, which damages DNA. Modern techniques shape and aim the beam to spare surrounding tissue.
  • Targeted therapy: drugs or antibodies aimed at a molecule present in the tumour but not in normal cells. This requires knowing the tumour's genetics, which is why cancer care increasingly begins with sequencing the tumour.
  • Immunotherapy: checkpoint inhibitors, and CAR-T cells (see Gene therapy), which turn the patient's own T cells against the cancer.
  • Therapeutic cancer vaccines: given to a patient who already has cancer, to train the immune system against markers found on that tumour. Because every tumour's mutations differ, these are often personalised, with an mRNA vaccine designed from the sequence of that patient's tumour; trials in melanoma and pancreatic cancer are under way. Russia announced in 2025 that its vaccine Enteromix, which uses viruses that destroy tumour cells and stimulate immunity, had completed early trials in colorectal cancer; such announcements are early-stage results, not approved treatments. Preventive vaccines are different: the HPV and hepatitis B vaccines prevent cancers by preventing the infections that cause them.
  • Better detection: because outcomes depend heavily on stage, much effort goes into finding cancer early, through screening, microRNA and DNA markers in blood (see Reading the genome), and imaging agents. One research approach uses quantum dots, nanocrystals that glow, coated with molecules that stick to tumour cells so that the tumour can be seen; nanotechnology is covered in its own chapter. The blood-marker route has a name of its own: a liquid biopsy looks for fragments of tumour DNA, whole tumour cells or tumour-derived RNA circulating in a blood sample, instead of cutting out a piece of the tumour itself. Its attraction is that blood can be drawn repeatedly and painlessly, which suits watching whether a treatment is working or whether a cancer is returning. It is not a universal substitute for a conventional biopsy: early tumours shed very little material, so a negative result does not rule cancer out, and a tissue sample is still what establishes the diagnosis in most cases.

In India, the commonest cancers are those of the breast, lip and oral cavity, cervix, lung and colon, with tobacco-related cancers accounting for a large share in men; the National Programme for Prevention and Control of Non-Communicable Diseases covers screening for oral, breast and cervical cancer.

When microbes outrun our drugs

Earlier (see From rDNA to gene editing) we saw how bacteria acquire resistance: a chance mutation lets one cell survive a drug, its descendants inherit the trait, and plasmids pass it sideways to unrelated bacteria by horizontal gene transfer. Heavy and careless use of antibiotics, in medicine and in poultry and livestock, selects for exactly these survivors. The result is antimicrobial resistance (AMR), which the WHO counts among the greatest threats to global health; India carries a heavy burden. Resistance is not limited to bacteria: Candida auris, a fungus that spreads in hospitals and resists several antifungal drugs, is one reason the WHO published a fungal priority pathogens list in 2022.

A bacterium carrying several resistance genes is called a superbug. One well-known resistance gene, NDM-1 (New Delhi metallo-beta-lactamase), produces an enzyme that destroys carbapenems, among the strongest antibiotics; the name, taken from where it was first reported in 2008, was itself the subject of protest in India.

Resistance is not always a matter of genes alone. Many bacteria do not live as free-floating single cells but settle on a surface and build a biofilm: a community held together in a sticky layer of material the cells themselves secrete. The layer slows the penetration of drugs and disinfectants, the cells deep inside grow slowly and so are less vulnerable to antibiotics that act on growing cells, and the close packing favours the sideways exchange of resistance genes. This is why infections on catheters, implants and heart valves are so hard to clear, and why dental plaque is the familiar example. A biofilm's tolerance is a property of the community and its structure; it is not the same thing as a resistance gene, and bacteria dispersed from a biofilm can become susceptible again.

Since new antibiotics are few and resistance to them is quick, biotechnology is looking for defences that can change as the microbe changes:

  • Phage therapy uses bacteriophages, the viruses that infect bacteria (see From rDNA to gene editing). A phage attacks a specific bacterium and, unlike a chemical drug, evolves along with its host. It also leaves the body's other bacteria alone. The difficulties are that each phage attacks a narrow range of bacteria, so the right phage must be matched to the patient's infection, and that regulatory systems are built around standard chemical drugs. Today phage therapy is used mainly on compassionate grounds in otherwise untreatable infections, with trials under way; it is a promising line, not a replacement for antibiotics.
  • Rapid diagnostics, including the CRISPR-based tests seen earlier (see From rDNA to gene editing), so that antibiotics are used only when needed and the right one is chosen.
  • Surveillance under the One Health approach (see DNA as the code of life), tracking resistance genes across humans, animals and the environment. India has a National Action Plan on AMR, and has restricted the use of colistin, a last-resort antibiotic, as a growth promoter in poultry.

What biotechnology contributes to medicine

ProductHow it is madeWhat it doesIndian example
Therapeutic proteinHuman gene in microbes or cultured cells (rDNA)Replaces a missing proteinRecombinant insulin
Monoclonal antibodyEngineered cells making one antibodyBlocks or marks a chosen targetBiosimilar trastuzumab
Recombinant or subunit vaccineOne antigen made by engineered cellsTrains immunity safelyCervavac (HPV); Shanvac-B (hepatitis B)
mRNA or DNA vaccineGenetic instructions for one antigenThe body makes the antigen itselfGEMCOVAC-OM; ZyCoV-D
Cell and gene therapyEditing or adding genes in the patient's cellsCorrects a cause, or arms the immune systemNexCAR19; BIRSA 101 (see Gene therapy)

Recent developments

Nobel Prize in Physiology or Medicine 2025: peripheral immune tolerance

Mary Brunkow, Fred Ramsdell and Shimon Sakaguchi shared the prize for their discoveries concerning peripheral immune tolerance. Sakaguchi identified a class of T cells that hold the immune system back rather than attack, now called regulatory T cells. Brunkow and Ramsdell traced a severe autoimmune disease in mice to the gene Foxp3, which was then shown to be the gene those cells depend on.

Why it matters: It explains why the immune system does not ordinarily attack the body that houses it, and that explanation cuts both ways in medicine. Too little restraint appears as autoimmune disease and as rejection of a transplant. Too much restraint is one reason tumours survive, because a tumour that attracts regulatory T cells is shielded from attack. Several therapies in this topic, from checkpoint inhibitors to cell therapies, are attempts to shift that balance deliberately.

Remember: Regulatory T cells (Tregs) and the Foxp3 gene they depend on. Peripheral tolerance acts on mature immune cells outside the thymus, as against central tolerance, which removes self-reactive cells inside it. 2025 medicine prize: Brunkow, Ramsdell, Sakaguchi.

Source: The Nobel Prize, Physiology or Medicine laureates

Last-month notes
  • Recombinant insulin: first rDNA medicine (1982). Type 1: beta cells destroyed, no insulin. Type 2: insulin resistance.
  • Immunity: innate (general) and adaptive (specific, remembered); B cells make antibodies, T cells kill. Antigen = marker; antibody = protein that binds it.
  • Monoclonal antibodies: identical copies of one antibody; Köhler and Milstein, Nobel 1984; names end in -mab. Checkpoint inhibitors: Nobel 2018.
  • Vaccine types: live attenuated (BCG, measles, OPV), inactivated (IPV, Covaxin), subunit/recombinant (hepatitis B, HPV), viral vector (Covishield), mRNA (GEMCOVAC-OM, 2023), DNA (ZyCoV-D, 2021, world's first human DNA vaccine).
  • Cervavac: India's first indigenous quadrivalent HPV vaccine (Serum Institute with DBT), 2022.
  • Malaria: Plasmodium changes surface antigens at each life stage, so natural infection gives no lasting immunity. RTS,S recommended by WHO 2021; R21/Matrix-M (Oxford and Serum Institute) October 2023.
  • Cancer: oncogenes (accelerator) and tumour suppressor genes (brake); benign vs malignant; metastasis. Chemotherapy and radiotherapy are not selective; targeted therapy, checkpoint inhibitors, CAR-T and therapeutic cancer vaccines are.
  • AMR: mutation plus plasmid-borne horizontal gene transfer; superbugs; NDM-1 (first reported 2008) destroys carbapenems; Candida auris; WHO fungal priority list 2022; National Action Plan on AMR; One Health.
  • Phage therapy: bacteriophages co-evolve with bacteria; narrow host range; used on compassionate grounds.

Statements to watch for

  • mRNA vaccines do not alter the recipient's DNA and do not enter the nucleus.
  • A vaccine supplies the antigen; the body makes the antibodies.
  • Monoclonal means one antibody against one antigen, not one dose or one patient.
  • RTS,S and R21 reduce malaria substantially but do not give complete protection.
  • Phage therapy targets bacteria, not viruses, and is not yet a general substitute for antibiotics.
  • HPV and hepatitis B vaccines prevent cancers by preventing infections; therapeutic cancer vaccines treat existing cancer.
  • A biofilm's drug tolerance comes from the community and its protective layer, not only from resistance genes.
  • A liquid biopsy samples tumour material circulating in blood; a negative result does not rule out cancer.

Revise and apply

Activities to check your understanding, not new content. Answer first, then press Check or Show answers. Multiple-choice questions are original, in the UPSC style, not past UPSC questions. A printable workbook with all activities is on the theme page.

Complete the mind map

Type the missing words, then check.

Medicines from biotechnology
Proteins as medicines
First recombinant medicine:
Missing in haemophilia: factors
Immune system
Make antibodies: cells
Kill infected cells: cells
Marker on a pathogen:
Vaccines
Whole weakened pathogen: live
Genetic instructions for one antigen: vaccine
Hard problems
Genes that drive cancer:
Viruses used against bacteria: therapy
Fill in the blanks
  1. Identical copies of a single antibody, grown from one clone of cells, are called antibodies.
  2. India's first indigenous quadrivalent HPV vaccine, launched in 2022, is .
  3. The world's first approved DNA vaccine for humans was India's .
  4. The malaria vaccine developed by Oxford with the Serum Institute of India is .
  5. Bacteria pass resistance genes sideways to unrelated bacteria on .
Match the vaccine to its type
  1. BCG
  2. Covaxin
  3. Cervavac
  4. Covishield
  5. GEMCOVAC-OM
True or false? Correct the false ones
  1. An mRNA vaccine changes the DNA of the person who receives it.
  2. Natural malaria infection gives lasting immunity against future attacks.
  3. Chemotherapy kills only cancer cells.
  4. Losing a tumour suppressor gene removes a brake on cell division.
  5. Phage therapy is used against bacterial infections, not viral ones.
Decode the headline

"WHO recommends a second malaria vaccine." (a) Why did a malaria vaccine take so much longer than vaccines for many viral diseases? (b) Name the two recommended vaccines and what both of them target.

UPSC-style question 1

Consider the following statements about mRNA vaccines:

  1. They deliver the genetic instructions for one protein of the pathogen.
  2. The protein is produced by the recipient's own cells.
  3. The mRNA is incorporated into the recipient's chromosomes.

Which of the statements given above are correct?

UPSC-style question 2

Which one of the following best explains why developing a vaccine against malaria has been unusually difficult?

Write in about 50 words

Why is antimicrobial resistance called a threat to modern medicine, and what can biotechnology offer against it? Answer in about 100 words.

0 words

The next question Medicine and agriculture are the visible face of biotechnology, but most of the organisms we put to work are doing humbler jobs: cleaning up spills and sewage, feeding crops and manufacturing fuels and enzymes. What can organisms do outside the laboratory and the clinic, and where does that capacity stop?